Vaxcyte, Inc.

Vaxcyte, Inc. announced that its management will participate in and host one-on-one meetings at two upcoming investor conferences. These include the Leerink Partners Therapeutics Forum from July 14-15, 2026, with meetings on July 15, and the BTIG Virtual Biotechnology Conference from July 28-29, 2026, with meetings on July 28. The company aims to engage with investors regarding its clinical-stage vaccine pipeline.

Vaxcyte announced the dosing of the first participant in its Phase 1, first-in-human study for VAX-A1, an investigational vaccine candidate for Group A Streptococcus (Group A Strep). The randomized, double-blind, placebo-controlled study in healthy adults aged 18-40 aims to evaluate safety, tolerability, and initial immunogenicity. Topline data from the study is anticipated in the second half of 2027. Group A Strep is a significant global public health challenge with no approved vaccine, causing approximately 800 million new cases and over 600,000 deaths annually.

Vaxcyte reported a significant increase in net loss for Q1 2026, reaching $(320.6) million, primarily driven by a substantial rise in research and development expenses to $312.8 million. The company bolstered its financial position by raising $601.8 million through a follow-on public offering. Vaxcyte also continued to invest in manufacturing capabilities, with capital expenditures for its facility buildout increasing to $218.9 million.

Vaxcyte reported a net loss of $320.6 million for Q1 2026, compared to $140.7 million in Q1 2025, driven by increased R&D expenses. The company announced the completion of enrollment for all three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) and the VAX-31 infant Phase 2 study. Vaxcyte also strengthened its balance sheet with approximately $2.7 billion in cash, cash equivalents, and investments as of March 31, 2026, following a $601.8 million net proceeds equity offering in February 2026.

Vaxcyte, Inc. announced the completion of enrollment for its VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) and the VAX-31 infant Phase 2 dose-finding study. Topline data for OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results in H1 2027. The company reported a strong cash position of $2.74 billion as of March 31, 2026, including $601.8 million in net proceeds from a February 2026 equity offering, and plans to initiate a Phase 1 study for VAX-A1 in mid-2026. Q1 2026 net loss widened to $320.6 million due to increased R&D expenses supporting clinical and manufacturing advancements.